Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents"

Transcription

1 D 012

2 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

3 DATA : 1 DATA : 2 3 DATA : UNGITEC 1

4 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126) (13)--D(pg/mL)

5 FUNGITEC 3

6 DATA : 2 1. Candida albicans 2. Candida glabrata 3. Candida parapsilosis 4. Candida tropicalis 5. Candida guilliermondii 6. Aspergillus fumigatus 7. Aspergillus flavus 8. Aspergillus niger 9. Cryptococcus neoformans 10. Mucor sp. 11. Trichosporon beigelii

7 FUNGITEC 5

8 DATA : pg/ml Cryptococcus neoformans C. neoformans (C) (mg dl 1 ) Pseudomonas aeruginosa 76.5 pg/ml (C) (pg ml 1 ) (mg dl 1 ) (mm h 1 )

9 FUNGITEC L2, Ph1, HL-4Extremely high risk group minor-bcr HL-4 VP-16Ara-C 34.2 pg /ml20 pg /ml B 3g/ 200mg 300mg 140mg/kg 100mg 140mg/kg 100mg/kg 140mg/kg 6mg/kg 2T 30mg/kg 200mg/kg 25mg/kg 30mg () ,300 18, (mg dl 1 ) mg 400mg 200mg mg/ B g/ 2g/ 400mg/ 2g/ 400mg/ 400mg/ 6g/ 400mg/ 4g/ 200mg/ 2g/ 400mg/ 4g/ 400mg / 400mg/ 400mg/ 160mg/ 20mg/ 400mg/ 2mg/ G-CSF 300g/300g/150g /75g / 2mg/ 300mg/ 10mg/ G-CSF 300g / 180mg/ 4g/ 0.3g/ () (mg dl 1 ) pg/mL 91.9pg/mL 42.35pg/mL 30.43pg/mL 7

10 FUNGITEC (pg ml 1 ) 300 G test/es CT 6/ / / / C. tropicalis C. tropicalis C. tropicalis C. tropicalis G test Es Candida tropicalis C. tropicalis C. tropicaliscandida Candida Candida albicans Aspergillus flavus Aspergillus fumigatus Cryptococcus neoformans Microsporum canis Trichophyton mentagrophytes Trichophyton rubrum Saccharomyces cerevisiae Staphylococcus epidermidis Staphylococcus aureus -Streptococcus hemolyticus 8

11 R R 9

12 10 R R R R R

13 D D R D D D D

14 R 1. Reiss, E. : Molecular immunology of mycotic and actinomycotic infections, pp.11-14, Elsevier, New York (1986) 2., pp , (1987) 3. Saito, H. et al. : Agr. Biol. Chem., 32, (1968) 4. Obayashi, T. et al. : Clin. Chim. Acta, 147, (1985) 5. Obayashi, T. et al. : Infect Immun., 53, (1986) 6. Obayashi, T. et al. : Prog. Clin. Biol. Res., 231, (1987) 7. 35, (1991) 8. Obayashi, T. et al. : J. Med.Vet.Mycol., 30, (1992) 9. Miyazaki, T. et al. : J. Clin. Lab. Anal., 6, (1992) , (1993) , (1993) 12. Rylander, R. and Goto, H. (eds) (1994) : Third glucan inhalation toxicity workshop. Commitee on organic dusts ICOH, report 1/ , (1994) 14. Obayashi, T. et al. : Lancet., 345, (1995) 15. pp (1994) 16. pp (1995) 17. pp (1995) 18. pp (1995) 19. Yasuoka, A. et al. : Clin. Diagn. Lab. Immunol., 3, (1996) 20. Yoshida, M. : J. Lab. Clin. Med., 128, (1996) 21., pp (1981) 22. Morita, T. et al. : FEBS Lett., 129, (1981) 23. Prog. Med.,7, (1987) 24. Tanaka, S. et al. : Carbohydr. Res., 218, (1991) 25. Aketagawa, J. et al. : J. Biochem., 113, (1993) 26., 23, , (1995) 27., 166, , (1993) 28. Tamura, H. et al. : Clin. Chim. Acta, 226, (1994) 29., pp , (1996) , (1996) R1.Iwasaki, H. et al. : A new diagnostic aid for deep mycosis associated with hematologic disease using (13) --D-glucan assay (G-test). Am. Soc. Mycrobiol., pp (1993) R2. (13) --D-glucan Miconazole CHEMOTHERPY,39, (1991) R3. R4., 154, , (1990) R5. Opportunistic Fungus Infection, 74, 61-69, (1985) R6. fluconazolechemotherpy, 41, , (1993) R7. Iwama, A. et al. : Improved survival from fungaemia in patients with haematological malignancies : Analysis of risk factors for death and usefulness of early antifungal therapy. Eur. J. Haematol., 51, (1993) R8. Hughes, W. T. et al. : Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 161, (1990) R9. Debra, K. et al. : Guidelaines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 163, 201 (1991) R10. Hughes, W. T. et al. : Guidelaines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 163, (1991) R11. Medicament News,1392, 1-3 ( ) R12. Medicament News,1392,4-6 ( ) R13. (13) --D-glucan endotoxin 1pp (1999) R14. Usami, M. et al. : Positive (13) --D-glucan in blood components and release of (13) --D-glucan from depth-type membrane filters for blood processing. TRANSFUSION : 42, (2002) R15. (13) --D- pp (2005) R16. (13) --D Tel Fax

15

16 Telephone: Facsimile : URL : T(U)

- 1 -

- 1 - - 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus

More information

16 2

16 2 1 16 2 3 4 5 6 7 6.02 6.10 6.02 6.02 8 6.03 6.02 6.10 6.03 6.02 9 6.03 6.03 6.10 6.09 6.03 6.02 6.02 6.10 6.09 6.03 6.03 10 2.02 2.41 Aspergillus niger Aspergillus brasiliensis Aspergillus niger Aspergillus

More information

A A

A A 3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1

More information

Key words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81

More information

小動物の皮膚真菌症

小動物の皮膚真菌症 Small Animal Dermatomycosis 日 本 大 学 生 物 資 源 科 学 部 獣 医 学 科 獣 医 臨 床 病 理 学 研 究 室 准 教 授 加 納 塁 Rui Kano, Veterinary Pathobiology. (Associate Professor) Nihon University College of Bioresouce Sciences 1. はじめに

More information

! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The

More information

名称未設定-1

名称未設定-1 Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA

More information

Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (<400/ml) before candidemia AMoL; acute monocytic leukemia VH; intravenous yperali

Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (<400/ml) before candidemia AMoL; acute monocytic leukemia VH; intravenous yperali Key words: candidemia, HA-test, Cand-Tec, D-arabinitol, Ĉ-d-glucan Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (

More information

HPM_442_F_TgCHG_1128

HPM_442_F_TgCHG_1128 3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med 2004 30 62-7 Guideline Centers for Disease

More information

日本皮膚科学会雑誌第122巻第2号

日本皮膚科学会雑誌第122巻第2号 J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot

More information

VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against

More information

日本皮膚科学会雑誌第119巻第5号

日本皮膚科学会雑誌第119巻第5号 I II 1 dermatophytosis tinea 1 2 3 tinea pedis Trichophyton rubrum 4 tinea manus 5 tinea unguium 2 candidiasis, candidosis 3 malassezia infection 4 sporotrichosis Sporothrix schenckii 5 dematiaceous fungal

More information

27 2 17 学 説 試 験 問 題 (B) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 Na + 2 K 3 kg mg/kg AUC. g/hr/m. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg. 4 Na + -K + -ATPase 5 a b c d e a, b a, e b,

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 24 25 26 27 1 28 1 1 2 2 3 3 k k 1 2 3 k 29 30 31 32 33 () 34 35 36 () 37 () () () 38 39 40 41 42 43 2 2 44 45 46 47 48 49 50 51 52 53 54 55

More information

Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,

More information

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF 2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF

More information

第82 回日本感染症学会総会学術集会後抄録(I)

第82 回日本感染症学会総会学術集会後抄録(I) β Aspergillus Aspergillus β in vitro in vivo α γ α γδ Streptococcus suis S. suis Chlamydia trachomatis C. trachomatis C. trachomatis C. trachomatis Chlamydia Helicobacter pylori H. pylori H. pylori H.

More information

日本皮膚科学会雑誌第121巻第14号

日本皮膚科学会雑誌第121巻第14号 World J Surg Burns Burns JTrauma Lancet Lancet Surg Gynecol Obste J Burn Care Rehabil BMJ Pediatr Emerg Care The Treatment of Burns Burns, A Team Approach Surg Gynecol Obstet NEnglJMed J Burn Care Rehabil

More information

山口英世先生

山口英世先生 Laboratory diagnosis of imported mycoses : how to safely execute laboratory examinations Hideyo YAMAGUCHI 5 1 6 1 1976 7 019-0395 359 Teikyo University Institute of Medical Mycology (TIMM) (359 Otsuka,

More information

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

More information

94.7 05.1 1 mm 2 3 1) 2) 3) 4 3- -2-3- -2-..... mm 5 ,,,, (15,000ppm) (15,000ppm) (1,000ppm) (5,000ppm) American Conference of Governmental Industrial Hygienists 3,000 6,000 12,000 18,000 6 g/ml Aspergillus

More information

Complex sleep apnea syndrome and sleep disordered breathing in patients with cardiovascular disease V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) Sleep J Clin

More information

2007 Vol.56 No.6 総説 丸山浩樹

2007 Vol.56 No.6 総説 丸山浩樹 Reprinted from RADIOISOTOPES, Vol.56,.6 June 2007 Japan Radioisotope Association http : //www.jrias.or.jp/ α β α β ε m z α µ µ α m z m z µ µ Curr. Opin. Biotechnol J. Proteome Res Rapid Commun. Mass

More information

DocuPrint C5450 ユーザーズガイド

DocuPrint C5450 ユーザーズガイド 1 2 3 4 5 6 7 8 1 10 1 11 1 12 1 13 1 14 1 15 1 16 17 1 1 18 1 19 1 20 1 21 1 22 1 23 1 24 1 25 1 26 27 1 1 28 1 29 1 30 1 31 1 2 12 13 3 2 10 11 4 9 8 7 6 5 34 24 23 14 15 22 21 20 16 19 18 17 2 35

More information

Bio-No.57/3....

Bio-No.57/3.... 2004. MAR. 3No.57 http://www.wako-chem.co.jp C O N T E N T S 2 Wako Bio Window No.57 MAR.2004 l l l l wako wako l l mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm Wako Bio Window No.57 MAR.2004 3 4 Wako Bio Window

More information

untitled

untitled 7 ( ). 1. 2. 3. 4. 5. 6. . 1. (C.difficile associated disease CDAD) 1) CDAD 60 72 2 CDAD Toxin CDAD 2) (1) C.difficile C.difficile (2) C.difficile (toxin A toxin B) toxin A toxin B (A+B+) toxin A toxin

More information

4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

More information

Lagoon11_0.qxd (Page 1)

Lagoon11_0.qxd (Page 1) 2008. 9 No.11 Contents 10 1 Lagoon, No. 11, 2008. 9 Column 1 Lagoon, No. 11, 2008. 9 Report 1 2 ph 18 ICRI 11 19 200831 24 17 13.8 N 124 08 54.7 E 60 Acropora sp. Acropora TOC DNA Lagoon, No. 11, 2008.

More information

1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J

More information

untitled

untitled 1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood

More information

Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae

Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae Key words: penicillin insensitive and resistant pneumococcus Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae 小 児

More information

橡アロマセラピー症状別処方例.PDF

橡アロマセラピー症状別処方例.PDF 1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

More information

The Heart Healthy Tocotrienol Complex Tocomin SupraBio

The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

a * *JECFA ADI - 2 -

a * *JECFA ADI - 2 - 5-10 ADI 5-10 a 7 1-3 4 5 b c a Letter to Editor 7 1-3 3 d b b a 1 1969 a Table 3 8 72.5% 2.5 60% 372 2 * Table 3 2.5 4 mg/kg 12 32% 60 62% * a 2.5 10 40% 20% 25 BALB/cAJcl 40% 55 C3H/HeNJcl-MTV+ 2.5 4

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

13

13 13070503030906 0003020600060105080207 000608020902010606 030601 06ィ ィエ02ィヲ ィェィ ィョ ツィェ06ィヲ 080201ィ ィコ02ィィ02ィヲ ィ ィコィ 0102ィャィィィコィ 04080301 07. 00.05020800020209ィ 0606ィャ II 000806030406080904 03030400020102

More information

knsp-09/ky082844139000005942

knsp-09/ky082844139000005942 1 4 17 10 : 50 11 : 50 2 4 17 15 : 00 16 : 00 1 4 17 16 : 00 17 : 00 2 4 18 10 : 50 11 : 50 1 4 17 8:50 9:20 2 4 17 9:20 9:50 3 4 17 9:50 10 : 20 4 4 17 10 : 20 10 : 50 5 4 17 10 : 50 11 : 20 6 4 17 11

More information

Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : takaiwa@nias.affrc.go.jp 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.

More information

2001 2003 2005 2006 2007 2008

2001 2003 2005 2006 2007 2008 2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65

More information

第82 回日本感染症学会総会学術集会後抄録(II)

第82 回日本感染症学会総会学術集会後抄録(II) Corydoras sterbai Kryptopterus bicirrhis Petitella georgiae Xiphophorus maculatus rpob Xba Mycobacterium szulgai Mycobacterium gordonae M. szulgai M. gordonae M. avium M. szulgai M. gordonae M. szulgai

More information

untitled

untitled ---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

特論2

特論2 Bull. Natl. Inst. Health Sci., 124 Special report Hazardous Food-Borne Fungi, and the Present and Future Approaches to the Mycotoxin Regulations in Japan CladosporiumPecinilliumAspergillus 17 1,545 1,065

More information

19 8 1970 20 10 4 1

19 8 1970 20 10 4 1 19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE

More information

Helicobacter pylori Helicobacter pylori Helkobacter pylori erythromycin (EM) Mueller Hinton broth (Difco) H. pylori Staphylococcus aureus ATCC 29213 Escherichia coli ATCC25922 amoxicillin (AMPC), clarithromycin

More information

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9 32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5

More information

小児感染免疫第27巻第4号

小児感染免疫第27巻第4号 364 2015 C 1 2 3 4 5 6 7 8 urinary tract infection UTI 2 1 UTI 1 3 5 2,3 4 1 UTI Escherichia coli E. coli 80 5 Enterococcus 1 UTI 83 78 53 98 5 WBCs HPF 73 81 81 83 or 93 72 ororor 99.8 70 4 Key words

More information

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD

24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich

More information

O16200

O16200 1 0.9. Fe(3+) 161821) 21) 57) 0.11. 24-72 1 8001000ppm 18), 24) 18) (1) : ; 1) 24) (2) : ; 1 1618) ; 24-72 ; 8001000ppm30 (3) : ( ) ; ; (4) : 12 (5) : (7) * : 1 * : ( ) 1 ; 2 ; ; 23) *: *: 0.12. * 11618)

More information

Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal

More information

胆石症

胆石症 ,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic

More information

Table 1. Antimicrobial drugs using for MIC

Table 1. Antimicrobial drugs using for MIC Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive

More information

Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)

More information

2007050781......_.L.O...z.W

2007050781......_.L.O...z.W a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

More information

2種の(1→3)-β-D-グルカン測定試薬の真菌に対する反応性の比較

2種の(1→3)-β-D-グルカン測定試薬の真菌に対する反応性の比較 Comparison of the reactivity of two kinds of (1 3)- -D-glucan measurement reagents to fungi Tadashi Matsubayashi and Tomoyuki Yamazaki Measurements of (1 3)- -D-glucan are widely used for the diagnosis

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

Yasokarva, D. (Murata, S.) Mechanisms of Copper Toxicity in Saccharomyces cerevisiae Determined by Microarray Analysis (Kitagawa, E.) (Iwahashi, Y) Nakagawa, R. Hashido, T. (Iwahashi. H.) Environ. Toxicol.,

More information

x [1] Palmer Jeffrey, B. and M. Hiiemae Karen, (propulsion). (1343-8441), 1997. 1(1): p. 15-30. [2] Saitoh, E., et al., Chewing and food consistency: effects on bolus transport and swallow initiation.

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

untitled

untitled COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5

More information

History I COE

History I COE 2008 108-8641 5-9-1 TEL 03-5791-6334FAX 03-5791-6335 e-mailgakufu@lisci.kitasato-u.ac.jp 228-8555 1-15-1 TEL 042-778-9760FAX 042-778-9761 e-mailnyushi@kitasato-u.ac.jp URL http://www.kitasato-u.ac.jp/lisci/index.html

More information

日本糖尿病学会誌第58巻第3号

日本糖尿病学会誌第58巻第3号 l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ

More information

2

2 No.7 DATA FILE report MEIJI LIFE FOUNDATION OF HEALTH AND WELFARE 2 3 MQ MQ M Q 4 MQ MQ 5 MQ 12 1 8 5 4 3 2 1 18 18 199 219 2 239 22 259 24 26 MQ P.5P.1 P.1 vs 6 4 2 1984 1987 199 1993 1996 1999 6 5 4

More information

untitled

untitled Fig.1 t O O N,N p n J J J J J t J J J J J J J J J J J t t J J J J J J J J J p Fig.2 p t Fig.3 Fig.4 synanti p Table1 Table2t Table2 synanti antisyn synanti synanti Fig.5 syn anti anti Fig.6 Table3 Table4

More information

ます しかし 近 年 では 市 中 感 染 症 の 原 因 菌 としても 認 識 されるよ うになってきています 特 に 腎 盂 腎 炎 や 膀 胱 炎 などの 尿 路 感 染 で その 傾 向 が 顕 著 です これは 市 中 の 大 腸 菌 で ESBL 産 生 菌 が 増 加 し ており 腎

ます しかし 近 年 では 市 中 感 染 症 の 原 因 菌 としても 認 識 されるよ うになってきています 特 に 腎 盂 腎 炎 や 膀 胱 炎 などの 尿 路 感 染 で その 傾 向 が 顕 著 です これは 市 中 の 大 腸 菌 で ESBL 産 生 菌 が 増 加 し ており 腎 2015 年 12 月 30 日 放 送 ESBL 産 生 菌 感 染 症 をどう 治 療 するか 国 立 国 際 医 療 研 究 センター 病 院 国 際 感 染 症 センター 長 大 曲 貴 夫 ESBL 産 生 菌 ESBL とは Extended-spectrumβ-lactamase の 略 であり この 酵 素 を 産 生 する 菌 を ESBL 産 生 菌 と 呼 びます ESBL はβ-ラクタマーゼを

More information

日本皮膚科学会雑誌第121巻第11号

日本皮膚科学会雑誌第121巻第11号 β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis

More information

審査報告書(案)

審査報告書(案) 19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

01 Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson

01 Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson 01 01 Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Lesson Positive workshop course 1 Positive workshop

More information